Adamis pharmaceuticals receives a complete response letter from the fda regarding zimhi

San diego, nov. 16, 2020 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) (“adamis”) today announced that after the close of business and the u.s. markets on november 13th, it received a complete response letter (crl) from the u.s. food and drug administration (fda) regarding its new drug application (nda) for adamis' zimhi™ high dose naloxone injection product for the treatment of opioid overdose. the crl stated that the fda determined it cannot approve the nda in its present form and provided recommendations needed for resubmission.
ADMP Ratings Summary
ADMP Quant Ranking